Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company is headquartered in San Diego, California and currently employs 42 full-time employees. The firm develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The firm`s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The firm commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.
Website: biocept.com



Growth: Bad revenue growth rate -64.7%, there is slowdown compared to average historical growth rates 79.6%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -33.3%. On average the margin is decreasing steadily. Gross margin is low, -3.4%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$6.90 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 0.0% higher than minimum and 99.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 1.8x by EV / Sales multiple , the company can be >100% undervalued

Key Financials (Download financials)

Ticker: BIOC
Share price, USD:  (0.0%)0.4349
year average price 1.4592  


year start price 9.3900 2023-04-21

max close price 9.3900 2023-04-21

min close price 0.4349 2023-10-24

current price 0.4349 2024-04-19
Common stocks: 17 620 668

Dividend Yield:  0.0%
Last revenue growth (y/y):  -64.7%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  79.6%
Historical growth of EBITDA:  ---
EV / Sales: 0.0x
Margin (EBITDA LTM / Revenue): -33.3%
Fundamental value created in LTM:
Market Cap ($m): 8
Net Debt ($m): -6
EV (Enterprise Value): 2
Price to Book: 26.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-08-30Seeking Alpha

Biocept, Inc. (BIOC) Business Update Conference Call (Transcript)

2023-08-25InvestorPlace

7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole

2023-08-14Proactive Investors

Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference

2023-06-21Proactive Investors

Biocept appoints Antonino Morales as president and chief executive officer

2023-06-05Proactive Investors

Biocept says poster presentation at ASCO highlights impressive performance of CNSide assay in detecting leptomeningeal metastases

2023-05-25InvestorPlace

Why Is Biocept (BIOC) Stock Down 42% Today?

2023-05-17Proactive Investors

Biocept shares to commence trading on split-adjusted basis

2023-04-17Proactive Investors

Biocept outlines plans to get CNSide assay system commercially available, looks back on the 2022 financial year
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol BIOC BIOC BIOC BIOC BIOC
reportedCurrency USD USD USD USD USD
cik 1M 1M 1M 1M 1M
fillingDate 2023-08-14 2023-05-10 2023-04-17 2022-11-21 2022-11-10
acceptedDate 2023-08-14 16:31:27 2023-05-10 17:05:11 2023-04-17 17:18:48 2022-11-21 16:10:55 2022-11-10 16:22:47
calendarYear 2023.000 2023.000 2022.000 2022.000 2022.000
period Q2 Q1 Q4 Q3 Q2
revenue 589 000 673 000 -10M 6M 11M
costOfRevenue 3M 3M 4M 6M 8M
grossProfit -2M -2M -15M -189 000 3M
grossProfitRatio -3.329 -3.499 1.419 -0.034 0.244
researchAndDevelopmentExpenses 409 000 1M 1M 1M 2M
generalAndAdministrativeExpenses 3M 3M 2M 3M 4M
sellingAndMarketingExpenses 250 000 715 000 835 000 975 000 2M
sellingGeneralAndAdministrativeExpenses 4M 4M 3M 4M 6M
otherExpenses 91 000 0 3000.000 0 0
operatingExpenses 4M 5M 4M 5M 8M
costAndExpenses 7M 8M 8M 11M 16M
interestIncome 0 0 0 0 0
interestExpense 50 000 46 000 47 000 52 000 155 000
depreciationAndAmortization 370 000 614 000 441 000 491 000 810 000
ebitda -6M -6M -18M -5M -4M
ebitdaratio -9.598 -9.634 1.766 -0.910 -0.404
operatingIncome -6M -7M -19M -6M -5M
operatingIncomeRatio -10.380 -10.547 1.809 -0.998 -0.480
totalOtherIncomeExpensesNet 3M -46 000 -44 000 32 000 -155 000
incomeBeforeTax -4M -7M -19M -6M -5M
incomeBeforeTaxRatio -6.165 -10.615 1.813 -0.992 -0.495
incomeTaxExpense 141 000 92 000 -125 000 -32 000 0
netIncome -4M -7M -19M -6M -5M
netIncomeRatio -6.165 -10.752 1.801 -0.987 -0.495
eps -3.500 -12.320 -1.090 -0.320 -0.340
epsdiluted -3.500 -12.320 -1.090 -0.320 -0.340
weightedAverageShsOut 1M 580 813 17M 17M 15M
weightedAverageShsOutDil 1M 587 355 17M 17M 16M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Balance Sheet Statement

Property 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol BIOC BIOC BIOC BIOC BIOC
reportedCurrency USD USD USD USD USD
cik 1M 1M 1M 1M 1M
fillingDate 2023-08-14 2023-05-10 2023-04-17 2022-11-21 2022-11-10
acceptedDate 2023-08-14 16:31:27 2023-05-10 17:05:11 2023-04-17 17:18:48 2022-11-21 16:10:55 2022-11-10 16:22:47
calendarYear 2023.000 2023.000 2022.000 2022.000 2022.000
period Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 7M 7M 13M 18M 23M
shortTermInvestments 0 0 0 0 0
cashAndShortTermInvestments 7M 7M 13M 18M 23M
netReceivables 800 000 1M 2M 16M 17M
inventory 551 000 704 000 757 000 2M 2M
otherCurrentAssets 876 000 500 000 538 000 949 000 1M
totalCurrentAssets 9M 9M 16M 37M 44M
propertyPlantEquipmentNet 13M 14M 14M 14M 14M
goodwill 0 0 0 0 0
intangibleAssets 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0
longTermInvestments 0 0 0 0 0
taxAssets 0 0 0 0 0
otherNonCurrentAssets 386 000 386 000 386 000 392 000 496 000
totalNonCurrentAssets 13M 14M 15M 14M 14M
otherAssets 0 0 0 0 0
totalAssets 22M 23M 31M 51M 58M
accountPayables 1M 2M 2M 3M 5M
shortTermDebt 2M 2M 2M 2M 2M
taxPayables 0 0 0 0 0
deferredRevenue -526 000 0 0 0 0
otherCurrentLiabilities 2M 1M 2M 2M 3M
totalCurrentLiabilities 5M 4M 6M 7M 10M
longTermDebt 10M 10M 10M 10M 10M
deferredRevenueNonCurrent 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0
otherNonCurrentLiabilities 7M 6M 6M 11M 6M
totalNonCurrentLiabilities 17M 16M 17M 16M 16M
otherLiabilities 0 0 0 0 0
capitalLeaseObligations 11M 12M 12M 12M 12M
totalLiabilities 22M 21M 22M 24M 26M
preferredStock 0 0 0 0 0
commonStock 0 2000.000 2000.000 2000.000 2000.000
retainedEarnings -309M -306M -298M -280M -274M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0
othertotalStockholdersEquity 310M 308M 307M 307M 307M
totalStockholdersEquity 290 000 2M 9M 28M 32M
totalEquity 290 000 2M 9M 28M 32M
totalLiabilitiesAndStockholdersEquity 22M 23M 31M 51M 58M
minorityInterest 0 0 0 0 0
totalLiabilitiesAndTotalEquity 22M 23M 31M 51M 58M
totalInvestments 0 0 0 0 0
totalDebt 12M 12M 12M 12M 12M
netDebt 5M 5M -788 000 -6M -11M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Cash Flow Statement

Property 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol BIOC BIOC BIOC BIOC BIOC
reportedCurrency USD USD USD USD USD
cik 1M 1M 1M 1M 1M
fillingDate 2023-08-14 2023-05-10 2023-04-17 2022-11-21 2022-11-10
acceptedDate 2023-08-14 16:31:27 2023-05-10 17:05:11 2023-04-17 17:18:48 2022-11-21 16:10:55 2022-11-10 16:22:47
calendarYear 2023.000 2023.000 2022.000 2022.000 2022.000
period Q2 Q1 Q4 Q3 Q2
netIncome -4M -7M -19M -6M -8M
depreciationAndAmortization 370 000 614 000 438 000 407 000 810 000
deferredIncomeTax 0 -336 000 0 0 0
stockBasedCompensation 209 000 316 000 -137 000 462 000 3M
changeInWorkingCapital 2M 20 000 14M 378 000 -663 000
accountsReceivables 312 000 1M 14M 2M -4M
inventory 153 000 53 000 1M 352 000 402 000
accountsPayables 347 000 -39 000 -1M -2M -3M
otherWorkingCapital 882 000 -1M 387 000 120 000 0
otherNonCashItems -2M 336 000 141 000 222 000 0
netCashProvidedByOperatingActivities -3M -6M -4M -4M -5M
investmentsInPropertyPlantAndEquipment -97 000 -91 000 -136 000 -356 000 -315 000
acquisitionsNet 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0
otherInvestingActivites 75 000 0 0 0 0
netCashUsedForInvestingActivites -22 000 -91 000 -136 000 -356 000 -315 000
debtRepayment -160 000 -234 000 -59 000 -621 000 -501 000
commonStockIssued 4M 396 000 1000.000 145 000 94 000
commonStockRepurchased 0 0 0 0 0
dividendsPaid 0 0 0 0 0
otherFinancingActivites -431 000 0 -688 000 0 -242 000
netCashUsedProvidedByFinancingActivities 3M 162 000 -746 000 -476 000 -649 000
effectOfForexChangesOnCash 0 0 0 0 0
netChangeInCash -141 000 -6M -5M -5M -5M
cashAtEndOfPeriod 7M 7M 13M 18M 23M
cashAtBeginningOfPeriod 7M 13M 18M 23M 28M
operatingCashFlow -3M -6M -4M -4M -5M
capitalExpenditure -97 000 -91 000 -136 000 -356 000 -315 000
freeCashFlow -3M -6M -4M -4M -5M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Earning call transcript

2022 q3
2022-11-28 ET (fiscal 2022 q3)

Press-releases

Show financial reports only

2023-09-21 12:00 ET
Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases
2023-09-08 12:00 ET
Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics
2023-09-05 12:00 ET
Biocept to Participate in the H.C. Wainwright Global Investment Conference
2023-08-25 12:00 ET
Biocept to Hold Business Update Conference Call on August 30, 2023
2023-08-14 20:05 ET
Biocept Reports Second Quarter 2023 Financial Results
2023-08-14 12:00 ET
Biocept’s CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference
2023-06-20 20:15 ET
Biocept Names Antonino Morales as President and Chief Executive Officer
2023-06-14 20:05 ET
Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023
2023-06-05 12:00 ET
Scientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept’s CNSide™ Versus Cytology
2023-05-25 00:39 ET
Biocept Announces Pricing of $5.0 Million Underwritten Public Offering
2023-05-17 12:00 ET
Biocept Announces One-for-Thirty Reverse Stock Split
2023-05-10 20:05 ET
Biocept Reports First Quarter 2023 Financial Results
2023-04-17 20:10 ET
Biocept Reports 2022 Financial Results
2023-03-24 12:00 ET
Enrollment Begins in FORESEE Clinical Trial Using Biocept’s CNSide™ to Evaluate Patients with Leptomeningeal Metastases
2023-03-01 13:00 ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-01-06 11:55 ET
Biocept to Explore Strategic Alternatives and Implement Restructuring Plan
2022-11-21 21:05 ET
Biocept Reports Third Quarter 2022 Financial Results
2022-11-18 13:00 ET
Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors
2022-11-16 13:00 ET
Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System
2022-11-10 21:05 ET
Biocept Reports Second Quarter 2022 Financial Results
2022-10-19 12:00 ET
Biocept to Present at the LD Micro Main Event XV
2022-10-17 12:00 ET
Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System
2022-10-14 12:00 ET
Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
2022-10-06 12:00 ET
Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
2022-08-31 20:31 ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-08-22 20:15 ET
Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q
2022-08-16 12:00 ET
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
2022-06-27 12:00 ET
Biocept Appoints RSM as Independent Auditor
2022-06-22 11:30 ET
Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial
2022-06-07 12:00 ET
Biocept to Hold Business Strategy Conference Call Today
2022-05-23 20:05 ET
Biocept Reports First Quarter 2022 Financial Results
2022-05-16 20:05 ET
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
2022-04-08 20:05 ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-04-06 12:00 ET
Biocept Reports 2021 Fourth Quarter and Full Year Financial Results
2022-03-31 22:15 ET
Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance
2022-03-18 12:00 ET
Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022
2022-03-08 13:17 ET
Biocept Appoints Philippe Marchand as Chief Operating Officer
2022-03-04 13:00 ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-02-22 21:17 ET
Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer
2022-02-16 21:05 ET
Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer
2022-02-10 13:17 ET
Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer
2022-01-21 13:00 ET
Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant
2022-01-04 13:00 ET
Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10
2021-12-09 13:17 ET
Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain
2021-12-01 13:47 ET
Quest Diagnostics Now Offers Biocept's Liquid Biopsy Test for Lung Cancer, Expanding its Menu of Advanced Cancer Diagnostics
2021-11-22 18:56 ET
Clinical Validation is Completed for New COVID-19 Assay Designed by AEGEA Biotechnologies; Test Quantifies Viral Load to Determine Infection Level and Disease Progression
2021-11-22 13:17 ET
Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season
2021-11-18 13:17 ET
CORRECTING and REPLACING Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
2021-11-15 21:05 ET
Biocept Reports Third Quarter 2021 Financial Results
2021-11-09 13:17 ET
Study Shows Biocept’s Switch-Blocker Technology Enhances Performance of Conventional PCR-Based Liquid Biopsy Assays in Detecting Rare Cancer Mutations
2021-11-08 13:00 ET
Biocept to Report Third Quarter 2021 Financial Results and Host Investor Conference Call on November 15, 2021
2021-10-06 12:00 ET
Biocept to Present at the LD Micro Main Event on October 13
2021-09-22 12:17 ET
Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Students and Staff Amid Pandemic
2021-09-22 11:00 ET
Biocept Invites You to Join Us at the Benzinga Healthcare Small Cap Conference
2021-09-21 12:17 ET
Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations
2021-09-07 12:00 ET
Biocept to Present at Four Virtual Investor Conferences in September
2021-09-01 00:00 ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-08-19 12:34 ET
Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer
2021-08-16 20:05 ET
Biocept Reports Second Quarter 2021 Financial Results
2021-08-09 12:00 ET
Biocept to Report Second Quarter 2021 Financial Results and Host Investor Conference Call on August 16, 2021
2021-08-03 12:17 ET
Biocept Names David Karlander as Senior Vice President of Commercial Operations
2021-07-21 12:17 ET
Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells
2021-07-20 12:17 ET
Biocept Welcomes Linda Rubinstein and Antonino Morales to Board of Directors, Names Director Samuel Riccitelli as Chairman
2021-07-19 12:00 ET
Biocept to Participate in Two July Investment Conferences
2021-07-06 12:27 ET
Biocept Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer Biomarkers
2021-06-28 12:05 ET
Biocept Joins the Russell Microcap® Index
2021-06-22 12:17 ET
Biocept to Collaborate with Quest Diagnostics to Provide Advanced NGS-Based Liquid Biopsy Testing for Patients with Lung Cancer
2021-06-15 12:17 ET
Biocept Receives More Than 420,000 Samples During First Year of Offering COVID-19 Testing Service
2021-06-09 12:37 ET
Biocept and CLEARED4 Collaborate to Develop New Service for Managing COVID-19 Testing and Results Reporting for Biocept Customers
2021-06-03 12:00 ET
Biocept to Present at the LD Micro Virtual Invitational XI Conference on June 9, 2021
2021-06-02 20:05 ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-05-12 20:05 ET
Biocept Reports First Quarter 2021 Financial Results
2021-05-05 12:00 ET
Biocept to Report First Quarter 2021 Financial Results and Host Investor Conference Call on May 12, 2021
2021-04-28 12:17 ET
Biocept to Supply COVID-19 Testing Through Partnership With the Foundation for California Community Colleges
2021-04-21 12:17 ET
Biocept Announces Full Commercial Launch of CNSide™ Cerebrospinal Fluid Assay to Address Unmet Needs for Patients with Metastatic Brain Cancer
2021-04-14 12:05 ET
Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date
2021-04-07 20:05 ET
Biocept to Host Key Opinion Leader Webinar to Discuss Its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System
2021-04-01 21:00 ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-04-01 12:05 ET
Biocept to Host Key Opinion Leader Webinar on April 8 to Discuss its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System
2021-03-29 20:05 ET
Biocept Reports 2020 Fourth Quarter and Full Year Financial Results
2021-03-22 12:00 ET
Biocept to Report 2020 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 29, 2021
2021-03-09 12:00 ET
Biocept to Participate in Three Virtual Investment Conferences in March
2021-03-03 21:05 ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-03-02 13:07 ET
Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load
2021-03-02 13:07 ET
Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load
2021-02-23 13:07 ET
Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector™ Assay Kit for Non-Small Cell Lung Cancer Patients
2021-02-16 13:00 ET
Study Shows Biocept’s Target Selector™ Detects Mutations in “Quantity Not Sufficient” Specimens in Non-Small Cell Lung Cancer Patients
2021-02-03 13:00 ET
Biocept Provides Update on COVID-19 Testing with More than 250,000 Samples Received
2021-02-02 21:05 ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-01-12 13:00 ET
Biocept Issues Letter to Stockholders
2021-01-04 13:05 ET
Biocept to Present at H.C. Wainwright Virtual BioConnect Conference
2020-12-31 22:29 ET
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-12-30 13:05 ET
Biocept Enters into Laboratory Services Agreements with Two Southern California Regional Independent Physician Associations
2020-12-14 13:00 ET
Biocept Provides Business Update
2020-12-10 13:00 ET
Biocept's Target Selector™ Liquid Biopsy Demonstrated High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center
2020-12-01 16:30 ET
While The U.S. Faces Insufficient COVID-19 Testing Volume, EIR Healthcare Launches MedModLabs to Expand Access Immediately
2020-11-20 13:00 ET
Study Shows Biocept's Assays are Viable and Sensitive for Detecting Tumor Cells and Biomarkers in the Cerebrospinal Fluid of Patients with Breast and Lung Cancer that has Metastasized to the Central Nervous System
2020-11-17 13:05 ET
Results from Study Using Biocept's Target Selector™ Testing to Monitor Breast Cancer Disease Progression to be Presented at 2020 SABCS®
2020-11-12 21:05 ET
Biocept Reports Third Quarter 2020 Financial Results
2020-11-12 13:05 ET
Biocept Provides Update on COVID-19 Testing with More than 100,000 Samples Received
2020-11-09 13:05 ET
Biocept Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells
2020-11-05 13:05 ET
Biocept Awarded Broad Japanese Patent for the Use of Binding Entities in Combination with any Solid Surface to Capture and Detect any Target of Interest, including CTCs, from any Sample Type
2020-11-04 13:00 ET
Biocept to Release Third Quarter 2020 Financial Results and Host Investor Conference Call on November 12, 2020
2020-10-29 12:05 ET
Biocept Provides Update on COVID-19 Testing with More than 80,000 Samples Received
2020-10-21 12:00 ET
Biocept Appoints Samuel D. Riccitelli to its Board of Directors
2020-10-06 12:00 ET
Biocept Provides Update on COVID-19 Testing with More than 50,000 Specimens Received
2020-10-05 12:00 ET
Study Shows Biocept's Target Selector™ May Provide a More Robust Method for Detecting Lung Cancer Metastasis in Cerebrospinal Fluid than Cytology
2020-10-01 12:00 ET
Biocept to Present Study Results from Target Selector™ Testing in the Cerebrospinal Fluid of Patients with Lung Cancer at the IASLC Liquid Biopsy Meeting
2020-09-23 12:00 ET
Biocept Announces the Award of Japanese Patent for Primer-Switch Mutation Detection and Amplification Improvement Platform Used to Detect Rare Cell Mutations in Tissue, Blood and Cerebrospinal Fluid
2020-09-23 12:00 ET
Aegea Biotechnologies, Inc. Announces the Award of Japanese Patent for Primer-Switch Mutation Detection and Amplification Improvement Platform Used to Detect Rare Genetic Alterations and Variants
2020-09-21 12:00 ET
Biocept Announces that Highmark Has Made a Positive Coverage Determination on Target Selector™ Liquid Biopsy
2020-09-16 12:00 ET
Biocept Provides COVID-19 Testing Update with More than 35,000 Specimens Received
2020-09-14 12:00 ET
Aegea Biotechnologies, Inc. Advances to Semi-Finals of the $5M XPRIZE Rapid COVID Testing Competition
2020-09-09 12:00 ET
Biocept to Present at the H.C. Wainwright Global Investment Virtual Conference on September 14
2020-09-08 12:00 ET
Biocept Executes In-Network Provider Agreement with Health Net Federal Services Extending Coverage for its Liquid Biopsy Oncology Platform to the TRICARE West Region Network
2020-09-04 20:28 ET
Biocept Announces One-for-Ten Reverse Stock Split
2020-08-31 21:00 ET
LD Micro - 360 Companies Set to Present this Week
2020-08-31 13:24 ET
Biocept Provides COVID-19 Testing Update with More Than 21,000 COVID-19 Specimens Received and More than 20,000 Specimens Processed
2020-08-27 12:00 ET
Biocept to Present at the LD Micro 500 Virtual Conference
2020-08-24 12:00 ET
Biocept Names Michael Dugan, M.D. Chief Medical Officer and Medical Director
2020-08-20 12:30 ET
Biocept to Present at the Proactive One2One Virtual Investor Forum on August 25
2020-08-19 12:00 ET
Biocept Expands Agreement with MultiPlan to Include COVID-19 Testing
2020-08-19 09:00 ET
Aegea Biotechnologies, Inc. Announces the Issuance of U.S. Patent for Primer-Switch Nucleic Acid Probes for the Detection of Rare Genetic Events and for PCR Amplification Improvements
2020-08-18 12:00 ET
Biocept Awarded US Patent for proprietary Primer-Switch Mutation Detection and Amplification Improvement Platform Used to Detect Rare Cell Mutations, Including Cancer Biomarkers
2020-08-13 12:00 ET
Biocept Announces Agreement with Healthcare Group to Provide COVID-19 Testing to Multi-State Locations
2020-08-12 20:05 ET
Biocept Reports Second Quarter 2020 Financial Results
2020-08-06 12:00 ET
Biocept Announces Agreement with Aegea Biotechnologies to Develop New, Highly Sensitive PCR-based COVID-19 Assay Utilizing Patented Switch-Blocker PCR Technology
2020-08-05 13:00 ET
LD Micro Announces Preliminary List of Presenters for the LD 500
2020-08-04 12:00 ET
Biocept to Release Second Quarter 2020 Financial Results and Host Investor Conference Call on August 12, 2020
2020-08-03 12:00 ET
Biocept Reaches COVID-19 Testing Milestone with More than 7,000 Specimens Received and More than 6,500 Specimens Processed
2020-07-16 12:05 ET
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Both Support Biocept Proposal to Authorize the Reverse Split of Common Shares
2020-06-30 12:05 ET
Biocept Awarded Canadian Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells, from a Biological Fluid Sample such as Blood or Cerebrospinal Fluid
2020-06-24 12:05 ET
Biocept Enters Into Agreement with Reference-based Pricing Network Medical Cost Containment Professionals, LLC to Process Out-of-Network Claims
2020-06-22 12:05 ET
Biocept Announces the Availability of 10,000 Specimen Collection Kits for RT-PCR COVID-19 Testing
2020-06-05 12:05 ET
Biocept to Relocate Corporate Offices and CLIA-Certified Laboratory to New San Diego Location
2020-05-29 12:30 ET
Data Affirming Biocept's Target Selector™ Platform Identifies Cancer Mutations in Cerebrospinal Fluid Presented at ASCO 2020 Virtual Scientific Program
2020-05-20 12:05 ET
Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
2020-05-14 12:05 ET
Biocept Expands its Menu of Molecular Assay Kit Offering with Release of its Target Selector™ BRAF Kit for Clients' Use in Their Own Laboratories
2020-05-13 20:05 ET
Biocept Reports First Quarter 2020 Financial Results
2020-04-29 12:05 ET
Biocept to Release First Quarter 2020 Financial Results and Host Investor Conference Call on May 13, 2020
2020-04-28 12:05 ET
Biocept Announces CE-IVD Mark and Availability of its Target Selector™ EGFR Molecular Assay Kit in Europe
2020-04-20 12:05 ET
Biocept Launches Unique Line of Molecular Assay Kits for Detection of Key Oncogene Mutations Based on its Proprietary Target Selector™ Technology Validated for Use in Both Tissue and Blood Samples
2020-04-14 13:00 ET
Biocept Announces Pricing of $10.3 Million Registered Direct Offering Priced At-The-Market
2020-04-09 23:17 ET
Biocept to Begin COVID-19 Testing
2020-04-09 12:05 ET
Brazil Patent Granted for Biocept's Target Selector™ Oncogene Mutation Enrichment and Detection Platform
2020-04-02 12:05 ET
Australia Patent Issued for Primer-Switch Mutation Detection and Amplification Platform
2020-03-26 12:05 ET
Biocept Enters into Laboratory Services Agreement with Second California-Based Independent Physician Association
2020-03-25 20:05 ET
Biocept Reports 2019 Fourth Quarter and Full Year Financial Results
2020-03-18 12:05 ET
Biocept to Release 2019 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 25, 2020
2020-03-09 12:05 ET
Newly Published Data in Journal of Clinical Pathology Provides Clinical Validation for Biocept's Target Selector™ qPCR Assay to Identify Cancer-Associated Mutations
2020-03-05 13:30 ET
Biocept Announces Pricing of $6.6 Million Registered Direct Offering Priced At-The-Market
2020-03-02 13:30 ET
Biocept Announces Pricing of $9.2 Million Registered Direct Offering Priced At-The-Market
2020-02-14 13:05 ET
Biocept Appoints Cory J. Dunn Senior Vice President of Commercial Operations
2020-02-10 13:05 ET
Biocept Enters into Laboratory Services Agreement with California-Based Independent Physician Association
2020-02-04 13:05 ET
Biocept to Present at the 22nd Annual BIO CEO & Investor Conference
2020-01-14 13:05 ET
Biocept Announces Validation and Availability of its Liquid Biopsy Platform for the Detection of Actionable Cancer Biomarkers in Cerebrospinal Fluid
2020-01-14 13:05 ET
Biocept Announces Validation and Availability of its Liquid Biopsy Platform for the Detection of Actionable Cancer Biomarkers in Cerebrospinal Fluid
2020-01-08 14:00 ET
Biocept, Inc. Awarded United States Patent for the Use of Antibodies in Combination with Any Solid Surface to Detect Any Target Cell of Interest - from Any Sample Type
2019-12-12 13:00 ET
Biocept Announces Closing of $10.0 Million Underwritten Public Offering
2019-12-09 14:15 ET
Biocept Announces Pricing of $10.0 Million Underwritten Public Offering
2019-12-03 13:05 ET
Biocept's Liquid Biopsy CTC Testing for Breast Cancer to Be Featured in Poster Presentation at the 2019 San Antonio Breast Cancer Symposium®
2019-11-21 13:05 ET
Biocept Announces the Launch of its Liquid Biopsy Test to Detect TRK Biomarkers in the Blood of Patients Diagnosed with Cancer
2019-11-13 21:05 ET
Biocept Reports Third Quarter 2019 Financial Results
2019-11-07 13:05 ET
Biocept Announces CE IVD Marks and Availability of its CEE-Sure® Blood Collection Tube and Sample Collection Shipping Kit in Europe
2019-11-06 13:05 ET
Biocept to Release Third Quarter 2019 Financial Results and Host Investor Conference Call on November 13, 2019
2019-11-04 13:05 ET
Biocept's Target Selector(TM) Tests and Kits to Be Featured in Six Poster Presentations at the 2019 Association for Molecular Pathology Annual Meeting
2019-10-07 12:05 ET
Biocept's Target Selector(TM) ctDNA Platform Demonstrates Single Copy Detection for EGFR, BRAF, and KRAS Mutations; Study Results Published in Peer-Reviewed Journal, PLOS ONE
2019-10-03 12:05 ET
Biocept Announces Issuance of South Korean Patent Covering its Target Selector(TM) Oncogene Mutation Enrichment and Detection Platform
2019-09-03 12:05 ET
Biocept to Present at Two Investment Conferences in September
2019-08-22 12:05 ET
High Sensitivity of Biocept's Target Selector(TM) Platform Using CEE-Sure(TM) Blood Collection Tubes to Be Featured in Poster Presentation at the 2019 IASLC World Conference on Lung Cancer
2019-08-13 12:05 ET
Biocept Receives Three Additional Patents Covering its Antibody and Microchannel Technology and Enhanced Detection of Cancer Cells
2019-08-12 20:05 ET
Biocept Reports Second Quarter 2019 Financial Results
2019-08-05 12:05 ET
Biocept to Release Second Quarter 2019 Financial Results and Host Investor Conference Call on August 12, 2019
2019-07-22 12:05 ET
Biocept Announces Laboratory Services Provider Agreement with BeaconLBS®
2019-06-18 12:05 ET
Biocept Announces Commercial Launch of Target Selector(TM) NGS Breast Panel, the Company's Second Multi-Gene Tumor-Specific Panel
2019-05-28 13:31 ET
Thinking about buying stock in Aurora Cannabis, Armata Pharmaceuticals, Biocept, Jumei International, or Nio?
2019-05-28 12:05 ET
Biocept Awarded Patent in China for its Circulating Tumor Cell Platform Expanding Intellectual Property Estate to 33 Issued Patents Globally
2019-05-01 12:05 ET
Biocept to Release First Quarter 2019 Financial Results and Host Investor Conference Call on May 8, 2019
2019-03-28 20:05 ET
Biocept Reports 2018 Fourth Quarter and Full Year Financial Results

SEC forms

Show financial reports only

SEC form 8
2023-08-22 00:00 ET
Biocept reported for 2023 q2
SEC form 10
2023-08-14 16:31 ET
Biocept reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Biocept reported for 2023 q2
SEC form 6
2023-06-21 16:06 ET
Biocept published news for 2023 q1
SEC form 8
2023-05-15 00:00 ET
Biocept reported for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Biocept reported for 2023 q1
SEC form 10
2023-04-17 00:00 ET
Biocept reported for 2022 q4
SEC form 8
2023-04-17 00:00 ET
Biocept published news for 2023 q1
SEC form 6
2023-04-03 08:00 ET
Biocept published news for 2023 q1
SEC form 6
2023-03-20 08:00 ET
Biocept published news for 2022 q4
SEC form 6
2023-01-06 07:01 ET
Biocept published news for 2022 q4
SEC form 8
2023-01-06 00:00 ET
Biocept published news for 2022 q4
SEC form 6
2022-11-21 16:31 ET
Biocept published news for 2022 q3
SEC form 10
2022-11-21 16:10 ET
Biocept reported for 2022 q3
SEC form 8
2022-11-21 00:00 ET
Biocept reported for 2022 q3
SEC form 10
2022-11-21 00:00 ET
Biocept reported for 2022 q3
SEC form 6
2022-11-18 08:10 ET
Biocept published news for 2022 q3
SEC form 6
2022-11-14 16:56 ET
Biocept published news for 2022 q3
SEC form 6
2022-11-14 08:01 ET
Biocept published news for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Biocept published news for 2022 q3
SEC form 10
2022-11-10 16:22 ET
Biocept reported for 2022 q2
SEC form 10
2022-11-10 00:00 ET
Biocept reported for 2022 q2
SEC form 6
2022-10-19 16:06 ET
Biocept published news for 2022 q3
SEC form 6
2022-08-22 16:34 ET
Biocept published news for 2022 q2
SEC form 6
2022-08-16 08:06 ET
Biocept published news for 2022 q2
SEC form 6
2022-07-14 06:07 ET
Biocept published news for 2022 q2
SEC form 6
2022-07-13 16:04 ET
Biocept published news for 2022 q2
SEC form 6
2022-06-27 16:06 ET
Biocept published news for 2022 q1
SEC form 6
2022-06-13 16:06 ET
Biocept published news for 2022 q1
SEC form 6
2022-05-24 16:01 ET
Biocept published news for 2022 q1
SEC form 8
2022-05-24 00:00 ET
Biocept reported for 2022 q1
SEC form 10
2022-05-23 14:42 ET
Biocept reported for 2022 q1
SEC form 10
2022-05-23 00:00 ET
Biocept reported for 2022 q1
SEC form 6
2022-05-16 16:12 ET
Biocept published news for 2022 q1
SEC form 6
2022-05-02 16:11 ET
Biocept published news for 2022 q1
SEC form 6
2022-04-12 16:02 ET
Biocept published news for 2022 q1
SEC form 6
2022-04-07 06:05 ET
Biocept published news for 2022 q1
SEC form 8
2022-04-07 00:00 ET
Biocept published news for 2022 q1
SEC form 10
2022-04-05 17:26 ET
Biocept published news for 2021 q4
SEC form 10
2022-04-05 00:00 ET
Biocept published news for 2021 q4
SEC form 6
2022-04-01 16:04 ET
Biocept published news for 2022 q1
SEC form 6
2022-04-01 06:04 ET
Biocept published news for 2022 q1
SEC form 8
2022-04-01 00:00 ET
Biocept published news for 2022 q1
SEC form 6
2022-03-24 16:02 ET
Biocept published news for 2021 q4
SEC form 6
2022-03-08 16:02 ET
Biocept published news for 2021 q4
SEC form 6
2022-02-16 16:21 ET
Biocept published news for 2021 q4
SEC form 6
2022-02-14 21:17 ET
Biocept published news for 2021 q4
SEC form 6
2022-01-31 07:03 ET
Biocept published news for 2021 q4
SEC form 6
2021-11-22 16:34 ET
Biocept published news for 2021 q3
SEC form 10
2021-11-15 16:43 ET
Biocept published news for 2021 q3
SEC form 6
2021-11-15 16:12 ET
Biocept published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Biocept published news for 2021 q3
SEC form 8
2021-11-15 00:00 ET
Biocept published news for 2021 q3
SEC form 10
2021-08-16 16:37 ET
Biocept published news for 2021 q2
SEC form 6
2021-08-16 16:12 ET
Biocept published news for 2021 q2
SEC form 10
2021-08-16 00:00 ET
Biocept published news for 2021 q2
SEC form 8
2021-08-16 00:00 ET
Biocept published news for 2021 q2
SEC form 6
2021-07-21 08:37 ET
Biocept published news for 2021 q2
SEC form 6
2021-07-20 16:28 ET
Biocept published news for 2021 q2
SEC form 6
2021-07-12 16:46 ET
Biocept published news for 2021 q2
SEC form 6
2021-06-15 16:30 ET
Biocept published news for 2021 q1
SEC form 6
2021-05-13 06:30 ET
Biocept published news for 2021 q1
SEC form 10
2021-05-12 17:00 ET
Biocept published news for 2021 q1
SEC form 6
2021-05-12 16:14 ET
Biocept published news for 2021 q1
SEC form 10
2021-05-12 00:00 ET
Biocept published news for 2021 q1
SEC form 6
2021-04-30 16:18 ET
Biocept published news for 2021 q1
SEC form 10
2021-03-31 16:22 ET
Biocept published news for 2020 q4
SEC form 6
2021-03-29 16:12 ET
Biocept published news for 2020 q4
SEC form 10
2020-11-13 21:39 ET
Biocept published news for 2020 q3
SEC form 6
2020-11-12 16:22 ET
Biocept published news for 2020 q3
SEC form 6
2020-10-21 08:32 ET
Biocept published news for 2020 q3